The corporate governance report covers the disclosure period from January 1 to December 31, 2025, detailing shareholder rights, board composition, and audit operations.
Major shareholder Hanmi Science holds 41.42%, minority shareholders 39.21%, maintaining a stable ownership structure.
On December 4, 2025, the company disclosed a 'Value-Up Plan' targeting total shareholder return of at least 20% by 2030, including minimum dividend, share buybacks, and RSU introduction.
Board consists of 10 directors (4 inside, 4 outside, 2 non-executive), with an outside director (Lee Young-gu) serving as both board chair and audit committee member.
Audit committee comprises three independent directors only, holding quarterly regular meetings and maintaining face-to-face communication with external auditors.
Governance weaknesses include non-compliance with 4-week advance shareholder meeting notice, lack of CEO succession policy, no formal outside director evaluation, and no cumulative voting.
Internal controls strengthened via compliance team operation, ISO 37301/37001 certifications, and AAA CP rating from Fair Trade Commission.
No material structural changes such as convertible bond issuance, controlling shareholder change, or merger occurred during the period.
Current period cash dividend of KRW 2,000 per share (dividend yield 0.40%), up from KRW 1,250 last year, with total shareholder payout ratio at 19.8% approaching the 20% target.
[AI Summary]This routine governance report has limited short-term price impact. However, the concretization of the value-up plan and enhanced audit committee independence are expected to positively influence mid-to-long-term shareholder value.